公开(公告)号：US20220211666A1

公开(公告)日：2022-07-07

申请号：US17609849

申请日：2020-05-07

Applicant: SYNACT PHARMA APS

Inventor： Thomas Engelbrecht Nordkild JONASSEN

IPC: A61K31/402 ,  A61K31/519 ,  A61P19/02 ,  A61P29/00

Abstract: The present invention relates to a composition comprising, separately or together, methotrexate (MTX) and (E)-N-trans-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium acetate (AP1189), or pharmaceutically acceptable derivatives thereof, for use in a method of treating an arthritis disease, such as rheumatoid arthritis.

公开(公告)号：US20230271922A9

公开(公告)日：2023-08-31

申请号：US17821500

申请日：2022-08-23

Applicant: SYNACT PHARMA APS

Inventor： Thomas BOESEN ,  Thomas Engelbrecht Nordkild JONASSEN ,  Hayley Ann REECE ,  Natalie Louise KELK ,  Alice Jane TURNER ,  Ross MCLELLAN

IPC: C07D207/335

CPC classification number: C07D207/335 ,  C07B2200/13

Abstract: The present disclosure relates to crystalline forms of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium salts having high solubility. The disclosure also relates to use of said crystalline forms in medicine.

公开(公告)号：US20210121418A1

公开(公告)日：2021-04-29

申请号：US17119142

申请日：2020-12-11

Applicant: SYNACT PHARMA APS

Inventor： Thomas Engelbrecht Nordkild JONASSEN

IPC: A61K31/155 ,  A61P13/12

Abstract: Provided is a composition comprising a phenyl pyrrole aminoguanidine derivative for use in a method of treating kidney disease, such as nephrotic syndromes.

公开(公告)号：US20250032449A1

公开(公告)日：2025-01-30

申请号：US18713745

申请日：2022-11-29

Applicant: SYNACT PHARMA APS

Inventor： Thomas Engelbrecht Nordkild JONASSEN

IPC: A61K31/402 ,  A61K31/519 ,  A61P19/02

Abstract: Provided is a combination therapy comprising optimised dosages of MTX and a compound of formula (I) for the treatment of rheumatoid arthritis.

公开(公告)号：US20240335423A1

公开(公告)日：2024-10-10

申请号：US18676679

申请日：2024-05-29

Applicant: SYNACT PHARMA APS

Inventor： Thomas BOESEN ,  Thomas Engelbrecht Nordkild JONASSEN ,  Hayley Ann REECE ,  Natalie Louise KELK ,  Alice Jane TURNER ,  Ross MCLELLAN

IPC: A61K31/402 ,  A61K9/20 ,  A61K9/28 ,  A61K31/519 ,  C07D207/335

CPC classification number: A61K31/402 ,  A61K9/20 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2846 ,  A61K31/519 ,  C07D207/335 ,  C07B2200/13

Abstract: The present disclosure relates to crystalline forms of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium salts having high solubility. The disclosure also relates to use of said crystalline forms in medicine.

公开(公告)号：US20230149351A1

公开(公告)日：2023-05-18

申请号：US17906375

申请日：2021-03-30

Applicant: SYNACT PHARMA ApS

Inventor： Thomas Engelbrecht Nordkild JONASSEN

IPC: A61K31/402 ,  A61P31/14 ,  A61K45/06

CPC classification number: A61K31/402 ,  A61K45/06 ,  A61P31/14

Abstract: Provided is a composition comprising a phenyl pyrrole aminoguanidine derivative for use in a method of treating viral disorders and diseases, including symptomatic viral disorders and diseases, including symptomatic COVID-19.

公开(公告)号：US20230114865A1

公开(公告)日：2023-04-13

申请号：US18065702

申请日：2022-12-14

Applicant: SYNACT PHARMA APS

Inventor： Thomas BOESEN ,  Thomas Engelbrecht Nordkild JONASSEN ,  Bent HØJGAARD

IPC: A61K31/402 ,  A61K31/519 ,  A61K9/20 ,  A61K9/28

Abstract: The disclosure relates to oral formulations for gastric delivery of a pharmaceutically acceptable salt of a phenyl pyrrole aminoguanidine compound.

公开(公告)号：US20230002319A1

公开(公告)日：2023-01-05

申请号：US17821500

申请日：2022-08-23

Applicant: SYNACT PHARMA APS

Inventor： Thomas BOESEN ,  Thomas Engelbrecht Nordkild JONASSEN ,  Hayley Ann REECE ,  Natalie Louise KELK ,  Alice Jane TURNER ,  Ross MCLELLAN

IPC: C07D207/335

Abstract: The present disclosure relates to crystalline forms of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium salts having high solubility. The disclosure also relates to use of said crystalline forms in medicine.